By Sarah Tilyou
Salt Lake City, UT.—Reactivation of cytomegalovirus (CMV) infection and preemptive therapy to prevent progression to CMV disease in recipients of allogeneic hematopoietic cell transplants (allo-HCT) is associated with significant financial and clinical burdens, according to a study from MD Anderson Cancer Center.
To determine the effect of preemptive therapy for CMV infection in allo-HCT recipients, Roy F. Chemaly, MD, MPH, the director of the Infection Control